AIRR - ANZCA Institutional Research Repository
Skip navigation
Please use this identifier to cite or link to this item: https://hdl.handle.net/11055/1278
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMitchell Ben_US
dc.contributor.authorDeckers Ken_US
dc.contributor.authorDe Smedt Ken_US
dc.contributor.authorRusso Men_US
dc.contributor.authorGeorgius Pen_US
dc.contributor.authorGreen Men_US
dc.contributor.authorGulve Aen_US
dc.contributor.authorVan Buyten JPen_US
dc.contributor.authorSmet Ien_US
dc.contributor.authorMehta Ven_US
dc.contributor.authorBaranidharan Gen_US
dc.contributor.authorRathmell Jen_US
dc.contributor.authorGilligan Cen_US
dc.contributor.authorGoss Ben_US
dc.contributor.authorEldabe Sen_US
dc.date2021-07-09-
dc.date.accessioned2025-01-14T04:19:29Z-
dc.date.available2025-01-14T04:19:29Z-
dc.date.issued2021-08-
dc.identifier.citation24(6):1024-1032.en_US
dc.identifier.issn1094-7159en_US
dc.identifier.urihttps://hdl.handle.net/11055/1278-
dc.description.abstractObjectives: The purpose of the ongoing follow-up of ReActiv8-A clinical trial is to document the longitudinal benefits of episodic stimulation of the dorsal ramus medial branch and consequent contraction of the lumbar multifidus in patients with refractory mechanical chronic low back pain (CLBP). We report the four-year outcomes of this trial. Materials and methods: ReActiv8-A is a prospective, single-arm trial performed at nine sites in the United Kingdom, Belgium, and Australia. Eligible patients had disabling CLBP (low back pain Numeric Rating Scale [NRS] ≥6; Oswestry Disability Index [ODI] ≥25), no indications for spine surgery or spinal cord stimulation, and failed conventional management including at least physical therapy and medications for low back pain. Fourteen days postimplantation, stimulation parameters were programmed to elicit strong, smooth contractions of the multifidus, and participants were given instructions to activate the device for 30-min stimulation-sessions twice daily. Annual follow-up through four years included collection of NRS, ODI, and European Quality of Life Score on Five Dimensions (EQ-5D). Background on mechanisms, trial design, and one-year outcomes were previously described. Results: At baseline (N = 53) (mean ± SD) age was 44 ± 10 years; duration of back pain was 14 ± 11 years, NRS was 6.8 ± 0.8, ODI 44.9 ± 10.1, and EQ-5D 0.434 ± 0.185. Mean improvements from baseline were statistically significant (p < 0.001) and clinically meaningful for all follow-ups. Patients completing year 4 follow-up, reported mean (±standard error of the mean) NRS: 3.2 ± 0.4, ODI: 23.0 ± 3.2, and EQ-5D: 0.721 ± 0.035. Moreover, 73% of participants had a clinically meaningful improvement of ≥2 points on NRS, 76% of ≥10 points on ODI, and 62.5% had a clinically meaningful improvement in both NRS and ODI and 97% were (very) satisfied with treatment. Conclusions: In participants with disabling intractable CLBP who receive long-term restorative neurostimulation, treatment satisfaction remains high and improvements in pain, disability, and quality-of-life are clinically meaningful and durable through four years.en_US
dc.subjectChronic low back painen_US
dc.subjectlong-term effecten_US
dc.subjectmultifidus muscle impaired neuromuscular controlen_US
dc.subjectrestorative neurostimulationen_US
dc.titleDurability of the Therapeutic Effect of Restorative Neurostimulation for Refractory Chronic Low Back Painen_US
dc.typeJournal Articleen_US
dc.type.contentTexten_US
dc.identifier.journaltitleNeuromodulation: Technology at the Neural Interfaceen_US
dc.identifier.doi10.1111/ner.13477en_US
dc.description.affiliatesMonash Clinical Research Pty Ltd, Clayton, VIC, Australia.en_US
dc.description.affiliatesGZA Hospitals, Wilrijk, Belgium.en_US
dc.description.affiliatesHunter Pain Clinic, Broadmeadow, NSW, Australia.en_US
dc.description.affiliatesSunshine Coast Clinical Research, Noosa Heads, QLD, Australia.en_US
dc.description.affiliatesPain Medicine of South Australia, Welland, SA, Australia.en_US
dc.description.affiliatesThe James Cook University Hospital, Middlesbrough, UK.en_US
dc.description.affiliatesAlgemeen Ziekenhuis Nikolaas, Sint-Niklaas, Belgium.en_US
dc.description.affiliatesSt. Bartholomew's Hospital, London, UK.en_US
dc.description.affiliatesLeeds Teaching Hospitals NHS Trust, Leeds, UK.en_US
dc.description.affiliatesBrigham and Women's Healthcare, Harvard Medical School, Boston, MA, USA.en_US
dc.description.affiliatesMainstay Medical BV, Amsterdam, The Netherlands.en_US
dc.description.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/34242440/en_US
dc.type.studyortrialClinical Trialen_US
dc.type.specialtyAnaesthesiaen_US
dc.type.specialtyPain Medicineen_US
dc.identifier.fulltextlinkhttps://www.neuromodulationjournal.org/article/S1094-7159(21)06232-2/fulltexten_US
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextrestricted-
item.cerifentitytypePublications-
item.fulltextWith Fulltext-
item.openairetypeJournal Article-
Appears in Collections:Scholarly and Clinical
Files in This Item:
File Description SizeFormat 
ReActiv8-A - Durability of the Therapeutic Effect of Restorative Neurostimulation for Refractory CLBP.pdf
  Restricted Access
1.12 MBAdobe PDFView/Open    Request a copy
Show simple item record

Page view(s)

22
checked on Jan 17, 2025

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.